| Stats | Twitter歴 3,690日（2009/04/14より） |
ツイート数 69,191（18.7件/日） |
表示するツイート :
Naoto T Ueno, MD, PhD@teamoncology
A Rare Genetic Mutation Leads to Cancer. The Fix May Already Be in the Drugstore. - The New York Times. Clinical trials needed. https://www.nytimes.com/2019/05/17/health/gene-mutation-cancer.html…
posted at 03:50:58
Naoto T Ueno, MD, PhD@teamoncology
Entinostat is a HDAC inhibitor which reverses anti-HER2 drug resistance by regulating apoptotic pathway per our preclinical study. #endcancer https://twitter.com/brjcancer/status/1130150119616274440…
posted at 22:41:48
Naoto T Ueno, MD, PhD@teamoncology
@kadsho Thanks for mentioning about me. A very important stuff.
posted at 16:53:44
Naoto T Ueno, MD, PhD@teamoncology
@jancoferstevens @snowangelmrsp Agree!
posted at 16:52:53
Naoto T Ueno, MD, PhD@teamoncology
チーム医療なる言葉を医療従事者が素直に受け入れる時代になった、世の中が大きく変化したエビデンス。18年前はMDアンダーソンみたいなチーム医療は根付かせるはリソースが無いのと文化の違いで不可と抵抗されたが見事に変貌した。
posted at 09:07:37
Naoto T Ueno, MD, PhD@teamoncology
How to learn social sensitivity! Not an easy skill to learn. https://www.quora.com/What-is-the-best-way-to-learn-social-sensitivity-and-self-awareness…
posted at 14:41:15
Naoto T Ueno, MD, PhD@teamoncology
My week on Twitter 🎉: 10 Mentions, 105 Mention Reach, 23 Likes, 4 Retweets, 36K Retweet Reach. See yours with https://sumall.com/performancetweet?utm_source=twitter&utm_medium=publishing&utm_campaign=performance_tweet&utm_content=text_and_media&utm_term=f68614ae1b9f4c54edcfbdb9… https://pic.twitter.com/zFZGGK9NnJ
posted at 10:00:24
Naoto T Ueno, MD, PhD@teamoncology
A very interesting article. Anger issue also applies to cancer patients. Some patient have difficulties to let go the anger. https://twitter.com/time/status/1128317824399740933…
posted at 10:45:07
Naoto T Ueno, MD, PhD@teamoncology
This IL-1ß inflammatory pathway response is the downstream effect of inflammasome complex, which drug development is ongoing. An exciting area to seek new therapeutic opportunities for breast cancer. #endcancer https://twitter.com/immunol_papers/status/1126344315981258759…
posted at 03:10:08
Naoto T Ueno, MD, PhD@teamoncology
Completely lost. Latest slang. https://twitter.com/mewtailv2/status/1123692122664837120…
posted at 11:17:14
Naoto T Ueno, MD, PhD@teamoncology
@proton_therapy Very true. We probably need to change the coat every day. I have my coat washed after each clinic.
posted at 01:29:37
Naoto T Ueno, MD, PhD@teamoncology
@proton_therapy Ties is also an issue. I keep my lab coat buttoned but not a perfect solution.
posted at 22:37:32
Naoto T Ueno, MD, PhD@teamoncology
@sesiegler I wipe everyday. But I may have to do more.
posted at 21:17:31
Naoto T Ueno, MD, PhD@teamoncology
Smart phone use in the hospital is very common. How often do we clean our phone? Data suggest that the healthcare provider phone is very dirty and implicated as the cause of the opportunistic infection.
posted at 21:07:46
Naoto T Ueno, MD, PhD@teamoncology
Interferon alpha signature is upregulated in inflammatory breast cancer. Potential target? https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-019-1140-1… #talkIBC
posted at 23:56:41
Naoto T Ueno, MD, PhD@teamoncology
Our biggest fans this week: funnypop66, BisratDebeb, Drskrath. Thank you! via https://sumall.com/thankyou?utm_source=twitter&utm_medium=publishing&utm_campaign=thank_you_tweet&utm_content=text_and_media&utm_term=f68614ae1b9f4c54edcfbdb9… https://pic.twitter.com/ztu7nJJk1D
posted at 23:01:54
Naoto T Ueno, MD, PhD@teamoncology
Low EPA and GLA level noted in adipose (fat) tissue noted in inflammatory breast cancer compared to non-IBC. Is this because of decreased cell membrane rigidity of the cells? https://www.sciencedirect.com/science/article/pii/S0960977619304813… #endcancer
posted at 01:44:49
Naoto T Ueno, MD, PhD@teamoncology
@KILLARI15 @MDAndersonNews Agree with you. I am very lucky to work with her.
posted at 20:19:05
Naoto T Ueno, MD, PhD@teamoncology
What a great news for Texas!! Cancer research remains the priority in state of Texas. #EndCancer https://twitter.com/senjanenelson/status/1125775158696972288…
posted at 10:45:52
Naoto T Ueno, MD, PhD@teamoncology
My great nurse in the right lower corner representing National Nurses Week Poster of @MDAndersonNews #EndCancer We all appreciate all the nurses dedication. https://pic.twitter.com/8QuPqpTm5t
posted at 04:14:24
Naoto T Ueno, MD, PhD@teamoncology
A major headache, which I do not have a clear answer. ‘Can I take probiotics?’ https://twitter.com/jsoriamd/status/1125531340466786304…
posted at 22:52:59
Naoto T Ueno, MD, PhD@teamoncology
Very concerning. Now the safety of sunscreen questioned. Protecting from the sun is key for preventing skin cancer like melanoma. Need to know the fact and FDA need to guide us what exactly we need to do for the public safety. https://www.usatoday.com/story/news/health/2019/05/06/sunscreen-chemicals-absorb-your-bloodstream-fda-study/1123513001/…
posted at 22:43:29
Naoto T Ueno, MD, PhD@teamoncology
National Nurses Week started on May 6th. 12th is the International Nurse Day. Nurses are an integral part of our medical team. They provide care, compassion, & comfort that the doctors may not be able to provide. We appreciate their hard work. https://cnn.it/2WrRX12 #endcancer
posted at 21:46:08
Naoto T Ueno, MD, PhD@teamoncology
Three postdocs from @MDAndersonNews supported by @jcancerjp (Relay for Life in Japan) @myoncologydream award participated in Houston @RelayForLife ! They are conducting research and learning about patient advocacy in the USA. We are very proud of them. #endcancer https://pic.twitter.com/ZF7Tunf5no
posted at 02:34:08
Naoto T Ueno, MD, PhD@teamoncology
.@InflammatoryBCa is proud to report the unique immune profiles of inflammatory breast cancer at @CIR_AACR. The mast cell infiltration correlated with the poor response to neoadjuvant chemo. We are dissecting why mast cells infiltrate in IBC. #endcance http://cancerimmunolres.aacrjournals.org/content/early/2019/05/01/2326-6066.CIR-18-0619…
posted at 07:33:41
Naoto T Ueno, MD, PhD@teamoncology
CancerX Summit 2019 がんの課題を解決するために私達にできること http://teamoncology.blog39.fc2.com/blog-entry-209.html…
posted at 23:48:02
Naoto T Ueno, MD, PhD@teamoncology
【Dense vs non-dense data】Seamless continuous monitoring sounds important. How will we interpret the overloaded (dense) data produced by continuous monitoring? Stat is not robust enough to explain the dense data. Maybe AI will solve the issue?
https://hbr.org/2019/05/the-future-of-drug-trials-is-better-data-and-continuous-monitoring… #endcancer
posted at 03:10:25
Naoto T Ueno, MD, PhD@teamoncology
How to create a team that is productive and culturally fun to work and does not depend on a positional leader to keep productivity and the culture is very challenging!
posted at 02:01:13
Naoto T Ueno, MD, PhD@teamoncology
T-DM1 now approved in the USA for adjuvant setting for those who had residual disease after neoadjuvant therapy for HER2+ early breast cancer based on KATHERINE study. #bcsm https://shar.es/a0a6Uy
posted at 07:56:51
Naoto T Ueno, MD, PhD@teamoncology
Updates on Advanced Breast Cancer: Local Management and Other New Perspectives on 5/18. Meet @MDAndersonNews clinicians. A great way to network. http://bit.ly/2LoysoU https://pic.twitter.com/LOomAVWJwD
posted at 04:25:25
Naoto T Ueno, MD, PhD@teamoncology
We have two excellent investigator from Egypt for our @InflammatoryBCa research mtg. We are learning about the research related to IBC in Egypt. #endcancer #talkibc https://pic.twitter.com/EsjYFeSfdO
posted at 02:28:50
Naoto T Ueno, MD, PhD@teamoncology
It was a great pleasure to meet the 2018 top faculty and staff fundraiser with President @ppisters for the @MDAndersonNews Boot Walk. We had a chance to discuss new ideas and we renewed our excitement for the coming 2019 Bootwalk on Nov 9! #endcancer https://pic.twitter.com/jZZ82Gzesq
posted at 01:31:36
Naoto T Ueno, MD, PhD@teamoncology
Trastuzumab deruxtecan (DS-8201a) in pts with advanced HER2+ breast cancer previously treated w/trastuzumab emtansine: phase 1 study published by @TheLancet There is three ongoing phase III studies. @MDAndersonNews has all 3 studies. #bcsm https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30097-X/fulltext?rss=yes…
posted at 21:05:55
Naoto T Ueno, MD, PhD@teamoncology
My week on Twitter 🎉: 6 Mentions, 152 Likes, 54 Retweets, 146K Retweet Reach, 14 New Followers. See yours with https://sumall.com/performancetweet?utm_source=twitter&utm_medium=publishing&utm_campaign=performance_tweet&utm_content=text_and_media&utm_term=f68614ae1b9f4c54edcfbdb9… https://pic.twitter.com/xkpvDR9Y0x
posted at 10:00:18
Naoto T Ueno, MD, PhD@teamoncology
Our biggest fans this week: eClinicalTrial, CancerMedMDA, IBCradiation. Thank you! via https://sumall.com/thankyou?utm_source=twitter&utm_medium=publishing&utm_campaign=thank_you_tweet&utm_content=text_and_media&utm_term=f68614ae1b9f4c54edcfbdb9… https://pic.twitter.com/TpkD8MhQIt
posted at 23:06:55
Naoto T Ueno, MD, PhD@teamoncology
What a great story! I wish that I can meet my donor. My donor is from Japan, which the regulation does not allow stem cell recipient to meet the donors. You want to thank you so much for the gift of life but culturally you have to be sensitive. https://www.click2houston.com/news/boy-meets-bone-marrow-donor-all-the-way-from-israel… #endcancer
posted at 22:44:56
Naoto T Ueno, MD, PhD@teamoncology
Inflammatory Breast Cancer Promotes Development of M2 Tumor-associated Macrophages and Cancer Mesenchymal Cells Through a Complex Cytokine Network. Our clinical trial by rebastinib targets the macrophage so that we can help the patients. #endcancer #bcsm http://cancerres.aacrjournals.org/content/early/2019/05/01/0008-5472.CAN-17-2158…
posted at 22:38:04
Naoto T Ueno, MD, PhD@teamoncology
An excellent session about inflammatory breast cancer collaboration throughout the @MDAndersonNews Cancer Network and Global Academic Program at the GAP conference. Our future depends on collaboration. Collaboration is essential for a collective impact. #endcancer https://pic.twitter.com/zTgX1yCjgo
posted at 05:59:21
Naoto T Ueno, MD, PhD@teamoncology
なるほど。How Heisei era beauty trend had changed over 31 years. https://youtu.be/q5-mVB2Z5RQ
posted at 07:40:17
Naoto T Ueno, MD, PhD@teamoncology
天皇陛下のお言葉を聞いて涙が出てしまった。お疲れ様です。平成がいよいよ終わるのかと思う。３つ目の元号を経験するのかと思うと、感慨ぶかい。
posted at 17:29:36
Naoto T Ueno, MD, PhD@teamoncology
I listened
live to the last words of the emperor at 3 am CST. Gave me tears. Heisei era is over. I will now live three different eras during my life!
posted at 17:28:54
Naoto T Ueno, MD, PhD@teamoncology
.@InflammatoryBCa is very excited that we will expand our inflammatory breast cancer-related protocols to other sites in the USA through @MDAndersonNews Cancer Network. It allows for tackling rare diseases by enrolling a large number of patients. https://www.mdanderson.org/about-md-anderson/our-locations/md-anderson-cancer-network.html…
posted at 07:30:44
Naoto T Ueno, MD, PhD@teamoncology
MDアンダーソンがんセンターが全米で17番目に良い雇用主とランキングされました。文句は時々言っていますが、素晴らしいことの方が圧倒的に多い職場です。
https://www.forbes.com/best-large-employers/#77fa1861fb3e…
posted at 07:25:43
Naoto T Ueno, MD, PhD@teamoncology
Very proud to be working at MD Anderson. @MDAndersonNews ranked as one of the best employees, number 17 in the USA. It sure is a great place to work. I complain sometimes but there is more to praise than being negative. https://www.forbes.com/best-large-employers/?fbclid=IwAR1iurR1ehahicCRME_Lu4UqDWW7-vP4VnU1_rsYlB7M57ITZ1P0KqHAPVc#50120d8ffb3e…
posted at 07:24:59
Naoto T Ueno, MD, PhD@teamoncology
Tomorrow is the last day of #Heisei era in #Japan. The era last for 31 years. I graduated on the first year of Heisei. From 5/1, it will be the first year of #Reiwa Era. I feel kind of sad that one era, which I spent as a doctor, will end tomorrow. https://twitter.com/japantimes/status/1122746096437088261…
posted at 04:38:10
Naoto T Ueno, MD, PhD@teamoncology
The rate of germline mutation in inflammatory breast cancer is like in high-risk population per @DrBOvermoyer. @InflammatoryBCa did not show any difference in BRCA mutation rate in IBC compared to non-IBC. More studies needed. https://www.breastcarenetwork.com/news/inflammatory-breast-cancer-may-be-at-high-risk-of-germline-mutation…
posted at 23:28:38
Naoto T Ueno, MD, PhD@teamoncology
Agree that it provides a wrong perception of Japan. Japan is rapidly changing, which allows empowerment of women and diversity. But, Japan can do a better job. https://twitter.com/melanie_brock/status/1121525656792133632…
posted at 06:43:05
Naoto T Ueno, MD, PhD@teamoncology
【Avenger Endgame, what the conclusion means】The Video Contains Spoiler!
This is the best interpretation of the conclusion. It sure did make sense to me. Watch the video if you have seen the movie! https://youtu.be/cPElHY4pF6A
posted at 02:00:29
Naoto T Ueno, MD, PhD@teamoncology
【Avengers Endgame Review】
1. Is it great and fun? Yes
2. Is the plot complex? Yes. Need to know the previous story. Watch at least Avenger Infinity & the below Youtube.
4. How long? 3 h. Do not drink a lot before the movie. No Best timing for a toilet.
https://www.youtube.com/watch?v=TqHhzKyfSm4…
posted at 06:51:56
Naoto T Ueno, MD, PhD@teamoncology
Subcutaneous vs IV Herceptin for Patients With HER2+ Early Breast Cancer: Final Analysis of Phase 3 Randomized Clinical Trial. Same efficacy & safety. How much can we save financially by SC? At least, we can get rid of CVC for those who need monoRx. #bcsm https://jamanetwork.com/journals/jamaoncology/fullarticle/2730632…
posted at 16:05:52
Naoto T Ueno, MD, PhD@teamoncology
My week on Twitter 🎉: 12 Mentions, 100K Mention Reach, 250 Likes, 57 Retweets, 201K Retweet Reach. See yours with https://sumall.com/performancetweet?utm_source=twitter&utm_medium=publishing&utm_campaign=performance_tweet&utm_content=text_and_media&utm_term=f68614ae1b9f4c54edcfbdb9… https://pic.twitter.com/jGk2pPqU0P
posted at 10:00:16
Naoto T Ueno, MD, PhD@teamoncology
An important paper to read to understand the immunotherapy side effects. Using immune checkpoint inhibitor, 66% will have some kind of side effects. 14% will have a severe side effect. 0.45% can die from side effects. It is not a piece of cake. https://jamanetwork.com/journals/jamaoncology/fullarticle/2731143?guestAccessKey=56bdd518-bb2f-4468-89ed-5c9bb31cb685&utm_source=fbpage&utm_medium=social_jamaonc&utm_term=2270264468&utm_content=followers-article_engagement-text-tfl&utm_campaign=article_alert&linkId=66564647&fbclid=IwAR3nPMQd-yCTgFz8YErAez159ZB1o5Yapzu6i5sOpWcqWKfdKvgDJuA4fTc…
posted at 04:53:52
